Limits...
Case report: safety and efficacy of tocilizumab in a patient with rheumatoid arthritis and chronic hepatitis C.

Iebba F, Di Sora F, Tarasi A, Leti W, Montella T, Montella F - Case Rep Med (2012)

Bottom Line: The safety of tocilizumab in HCV patients is an open question.The safety was good with no adverse events and maintenance, during a six-month followup, of normal liver enzymes.These data suggest a good safety profile of tocilizumab in patients with rheumatoid arthritis and chronic hepatitis C virus pathology.

View Article: PubMed Central - PubMed

Affiliation: Division of Clinical Immunology, San Giovanni-Addolorata Hospital, 00184 Rome, Italy.

ABSTRACT
Tocilizumab is a monoclonal humanized anti-IL-6-receptor antibody used for the treatment of rheumatoid arthritis. The safety of tocilizumab in HCV patients is an open question. We report on safety and efficacy of tocilizumab in a 71-year-old female with rheumatoid arthritis and chronic hepatitis C. Monotherapy with tocilizumab (8 mg/kg every 4 weeks, i.v.) was prescribed after the discontinuation, determined by clinical inefficacy, of anti-TNF-alfa agents (adalimumab and, subsequently, etanercept). We have registered an optimal and rapid clinical response to tocilizumab with early remission (SDAI <3.3 since 4 weeks). The safety was good with no adverse events and maintenance, during a six-month followup, of normal liver enzymes. These data suggest a good safety profile of tocilizumab in patients with rheumatoid arthritis and chronic hepatitis C virus pathology.

No MeSH data available.


Related in: MedlinePlus

Rheumatoid arthritis activity (SDAI) during treatment with tocilizumab.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3295620&req=5

fig2: Rheumatoid arthritis activity (SDAI) during treatment with tocilizumab.

Mentions: The analysis of liver exams has shown the maintenance of normal liver function during all the followup. No signs of cirrhosis were detected. No other adverse events associated to tocilizumab treatment were registered during the observation period. The etoricoxib requirement, high at baseline (5 tablets/week), was reduced to 1 tablet/week after 2 weeks and to 0 tablet/week after 4 weeks. The results of this study were collected in Table 1. The course of AST, ALT, and GGT was shown in Figure 1. The evaluation of activity of rheumatoid arthritis with SDAI during the treatment with tocilizumab was illustrated in Figure 2.


Case report: safety and efficacy of tocilizumab in a patient with rheumatoid arthritis and chronic hepatitis C.

Iebba F, Di Sora F, Tarasi A, Leti W, Montella T, Montella F - Case Rep Med (2012)

Rheumatoid arthritis activity (SDAI) during treatment with tocilizumab.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3295620&req=5

fig2: Rheumatoid arthritis activity (SDAI) during treatment with tocilizumab.
Mentions: The analysis of liver exams has shown the maintenance of normal liver function during all the followup. No signs of cirrhosis were detected. No other adverse events associated to tocilizumab treatment were registered during the observation period. The etoricoxib requirement, high at baseline (5 tablets/week), was reduced to 1 tablet/week after 2 weeks and to 0 tablet/week after 4 weeks. The results of this study were collected in Table 1. The course of AST, ALT, and GGT was shown in Figure 1. The evaluation of activity of rheumatoid arthritis with SDAI during the treatment with tocilizumab was illustrated in Figure 2.

Bottom Line: The safety of tocilizumab in HCV patients is an open question.The safety was good with no adverse events and maintenance, during a six-month followup, of normal liver enzymes.These data suggest a good safety profile of tocilizumab in patients with rheumatoid arthritis and chronic hepatitis C virus pathology.

View Article: PubMed Central - PubMed

Affiliation: Division of Clinical Immunology, San Giovanni-Addolorata Hospital, 00184 Rome, Italy.

ABSTRACT
Tocilizumab is a monoclonal humanized anti-IL-6-receptor antibody used for the treatment of rheumatoid arthritis. The safety of tocilizumab in HCV patients is an open question. We report on safety and efficacy of tocilizumab in a 71-year-old female with rheumatoid arthritis and chronic hepatitis C. Monotherapy with tocilizumab (8 mg/kg every 4 weeks, i.v.) was prescribed after the discontinuation, determined by clinical inefficacy, of anti-TNF-alfa agents (adalimumab and, subsequently, etanercept). We have registered an optimal and rapid clinical response to tocilizumab with early remission (SDAI <3.3 since 4 weeks). The safety was good with no adverse events and maintenance, during a six-month followup, of normal liver enzymes. These data suggest a good safety profile of tocilizumab in patients with rheumatoid arthritis and chronic hepatitis C virus pathology.

No MeSH data available.


Related in: MedlinePlus